



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07K 14/47, A61K 38/17, G01N 33/68	A1	(11) International Publication Number: WO 97/42222 (43) International Publication Date: 13 November 1997 (13.11.97)
(21) International Application Number: PCT/GB97/01250 (22) International Filing Date: 8 May 1997 (08.05.97) (30) Priority Data: 9609521.1 8 May 1996 (08.05.96) GB 9621314.5 9 October 1996 (09.10.96) GB (71) Applicant (for all designated States except US): CYCLACEL LIMITED [GB/GB]; Marquis House, 67-68 Jermyn Street, London SW1Y 6NY (GB). (72) Inventors; and (75) Inventors/Applicants (for US only): BALL, Kathryn, Lindsay [GB/GB]; CRC Cell Transformation Research Group, Dept. of Biochemistry, University of Dundee, Dundee DD1 4HN (GB). LANE, David, Philip [GB/GB]; CRC Cell Transformation Research Group, Dept. of Biochemistry, University of Dundee, Dundee DD1 4HN (GB). (74) Agents: WALTON, Seán, M. et al.; Mewburn Ellis, York House, 23 Kingsway, London WC2B 6HP (GB).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: METHODS AND MEANS FOR INHIBITION OF CDK4 ACTIVITY (57) Abstract <p>p21^{WAF1} interacts with cyclin D1 and Cdk4. Peptide fragments of p21 inhibit the interaction and/or affect Cdk4 activity. The peptides, derivative peptides and non-peptidyl mimetics thereof are useful in affecting activity of Cdk4, such as RB phosphorylation, and cellular proliferation, indicative of therapeutic usefulness in treatment of tumours and other hyperproliferative disorders. Assay and screening methods allow identification of such modulators, especially inhibitors, of Cdk4 activity.</p>		